Inimex Pharmaceuticals

edit

Inimex Pharmaceuticals, Inc. is a clinical stage company focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body’s innate defenses without causing inflammation.

Milestones

edit

• 
  Inimex Pharmaceuticals received $22M in Series B funding. (6/2/08)
  Posted 6/4/09 at 2:03am
• 
  Inimex Pharmaceuticals received $4.5M in Series A funding. (7/6/04)
  Posted 6/25/09 at 11:19pm
• 
  Inimex Pharmaceuticals added John R. North as President & CEO.
  Posted 6/4/09 at 2:03am
• 
  Inimex Pharmaceuticals added Oreola Donini as Senior Director.
  Posted 6/4/09 at 2:03am
• 
  Inimex Pharmaceuticals added Martin (Marty) McConnell as CFO.
  Posted 6/4/09 at 2:03am

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/4/09

Sources

1. Inimex Pharmaceuticals Announces $2 Million Second Closing of Series A (inimexpharma.com) [edit]
2. Capital Funding Report [edit]